Collection of medical insurance payment pilot started! The original drug pays 105 times the price of the drug collection?

Text . . . Code Wanxuan guide reading: collection of health insurance payment linkage? The same consistent evaluation of drug payment standards is different! Recently, the Sichuan Medical Insurance Bureau issued a "notice on the issuance of centralized procurement and use of drugs by state organizations to expand the relevant drug medical insurance payment standards (draft for comments)" for public comments.
read this opinion, the author trance appeared three "at first glance" phenomenon.
First, the name of the document at first glance, thought it was issued by the State Health Insurance Administration, the fixed eye is Sichuan in the pilot;
soon some people began to question: why the original research drugs, with the volume of procurement of chinese medicine, the standard of payment for the standard of payment is different? In this paper, the author tried to use this draft and attachment, to analyze the health insurance bureau so operating is not "unexpected."
Why is the original drug payment standard 105 times more expensive than the amount of the original drug purchase standard than the amount of the purchase of medicine 105 times more expensive, that is to say, Entekave tablets, Shi Guibao payment price than Suzhou Dongrui difference of 105 times.
is the original research drug because it is not a quantity of procurement drug identity, it is not the main character.
in the centralized procurement activities in the first, the use of pilot enlargement does not have positive support in the back.
people have not won the bid, there is no contract between each other, although the Health Insurance Bureau as a strategic buyer, and what is the way? It would be contrary to the spirit of the market if the price paid for the original drug was lowered to one percent.
and the centralized procurement of drugs represented by volume procurement is the use of market spirit to be a great success.
Although this is said, but seems to see two turning points: First, the multiply difference is so obvious the price paid for the original research drug was made public, some original research drug enterprises, products inevitably embarrassed, the original I am such a status, I have no gold suspect? Do I have any medicines that are inflated? Ordinary people may also be numb, but really understand the medicine, understand the international market price, may be shocked to play a spirit; Isn't dynamite waiting to be sniped by Medicare's fine management operations? This sensitive topic is only related to the interests of enterprises, products to come forward to talk about, the Health Insurance Bureau is not willing to do more oppression.
If the same generic drug that has been evaluated consistently, why pay different standards in this Sichuan Health Insurance Bureau issued notice, it is worth noting that the same drug, the same is through the consistency evaluation, but the payment of health insurance is different, such as: Xin'an Pharmaceuticals Atovastatin calcium tablets (10mg) for 0.1353 yuan / tablet, the same specifications of the same packaging beijing Jialin Pharmaceuticals and Zhejiang Lepu Pharmaceuticals, the drug medical insurance payments are 2.3215 yuan / tablet and 2.6319 yuan / tablet, indicating that the health insurance bureau is probably in compliance with the spirit of the contract, market spirit.
I is in the collection and expansion, the second batch, the third batch of mining activities, the participating enterprises, products are selected by rotation province, some generic drugs originally and Sichuan Province missed fate, but Sichuan Province led the provincial health insurance payment standards, to take care of other provinces in replication, reference when the available space, can not be the province's volume procurement supply drug payment price "one size fits all".
This proves: as long as the contract implementation period, with the amount of procurement of pharmaceutical enterprises, products do not move, the Health Insurance Bureau will try not to move, as far as possible to maintain a national chess game, market competition price reduction is not in this overnight.
2 is to the same varieties directly affected by the purchase of pharmaceutical products, product regulations of non-banded procurement of pharmaceutical enterprises, products reflect the "step-by-step" policy, not only in accordance with the State Health Insurance Administration and other nine departments "on the national organization of drug centralized procurement and use of pilot expansion of regional implementation opinions" in the general direction, but also in the pilot phase to reduce resistance to the pharmaceutical industry, the market share of non-agent procurement of pharmaceutical enterprises, products to talk about, bright pay prices, encourage enterprises to change the price.
expect hospital doctors to go in line with the fine management measures of health insurance to go ahead with the implementation of the standard of payment of health insurance before including the purchase of pharmaceutical enterprises, products, may continue to bring gold sales.
, but after the payment standards are announced to the community, the benevolent see benevolence, the wise see wisdom, and perhaps there is indeed an unreasonable price phenomenon.
such as: some with the amount of procurement drug prices are too low, some non-volume procurement of drugs prices do not move the level is not a reasonable level? For some of the still existence of gold sales, expect hospital doctors to objectively understand.
health insurance bureau is cracking down on the phenomenon of gold, including tigers and flies together.
in the clinical rational use of comprehensive medical reform, hospital doctors in order to avoid patients, medical insurance doubts, should be over-the-counter procurement of drugs to patients to explain the reasons, clear the relationship.
In the author's opinion, if the hospital doctor can take the initiative to add a patient to sign the informed procedure, it is not difficult, but also for the construction of modern hospital management system at this stage can explore to do a small detail.
pointed out that: pay the price difference of 105 times the original research drugs and with the purchase of generic drugs are in the medical insurance reimbursement directory, patients must choose the original research drugs ah.
that's no problem in theory.
However, because some of the original research drugs because there is no collection of selected, many normal operation of the hospital is not able to, there is no will to ensure adequate inventory, but is responsible for, have the task to ensure that the amount of prescriptions for the purchase of drugs proportion.
no matter which price is paid, for both drugs, Medicare has included them in the Medicare Class A list to minimize the impact on patient out-of-payments.
to some of the original research drugs as the representative of the non-band procurement of drugs should be understood, did not choose it.
Looking forward to the document after the entry into force will be on stage and off the stage at the same time to promote the landing of the final author noted that Sichuan Province this notice involving 25 varieties, only corresponding to 503 standard drugs, there are many enterprises under the same generic name, products do not occupy a position on paper.
can be imagined, not on the list of enterprises, products corresponding to the payment price, will not be too high over these on the list.
because the market share of large non-band procurement of drugs have been talked about, responded to, what else is not convinced.
While the pilot of provincial payment standards at this stage has not yet completed the mature paradigm of adopting the same payment standards under the same generic name, it can already be inferred from this document and its annexes that that goal will come sooner.
Under the provincial medical insurance payment standards, has been clearly for the volume of procurement of pharmaceutical enterprises, product platform to speak: First, the purchase agreement for the current period corresponding to the payment price immediately linked, affecting more non-volume procurement of drug prescriptions to pay the price;
third is that even if the same generic name drug payment standards are absolutely uniform situation should also be issued in a timely manner pilot documents, it can be seen that this work is really impatient.
the purchase of large-band quantity has made good use of the law of market competition, and the reform of payment standards has also embarked on this road.
you either talk about it or "impeach" you.
.